Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1257

1.

Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.

Roland KL, Cloninger C, Kochi SK, Thomas LJ, Tinge SA, Rouskey C, Killeen KP.

Vaccine. 2007 Dec 12;25(51):8574-84. Epub 2007 Oct 26.

PMID:
18045752
2.

Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.

Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A, Nygren E, Tobias J, Walker R, Svennerholm AM.

Vaccine. 2013 May 7;31(20):2457-64. doi: 10.1016/j.vaccine.2013.03.027. Epub 2013 Mar 27.

3.

Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine.

Tokuhara D, Yuki Y, Nochi T, Kodama T, Mejima M, Kurokawa S, Takahashi Y, Nanno M, Nakanishi U, Takaiwa F, Honda T, Kiyono H.

Proc Natl Acad Sci U S A. 2010 May 11;107(19):8794-9. doi: 10.1073/pnas.0914121107. Epub 2010 Apr 26.

4.

Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.

Concha A, Giraldo A, Castañeda E, Martínez M, de la Hoz F, Rivas F, Depetris A, Svennerholm AM, Sack DA.

Bull Pan Am Health Organ. 1995 Dec;29(4):312-21.

PMID:
8605522
5.

Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae.

Tobias J, Lebens M, Bölin I, Wiklund G, Svennerholm AM.

Vaccine. 2008 Feb 6;26(6):743-52. doi: 10.1016/j.vaccine.2007.12.009. Epub 2007 Dec 26.

PMID:
18191006
6.

A review of the current status of enteric vaccines.

Levine MM, Noriega F.

P N G Med J. 1995 Dec;38(4):325-31. Review.

PMID:
9522876
7.

Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.

Kundu J, Mazumder R, Srivastava R, Srivastava BS.

FEMS Immunol Med Microbiol. 2009 Jul;56(2):179-84. doi: 10.1111/j.1574-695X.2009.00563.x. Epub 2009 May 5.

8.

Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study.

Leyten EM, Soonawala D, Schultsz C, Herzog C, Ligthelm RJ, Wijnands S, Visser LG.

Vaccine. 2005 Oct 17;23(43):5120-6.

PMID:
15982790
9.

Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial.

Clemens JD, Sack DA, Harris JR, Chakraborty J, Neogy PK, Stanton B, Huda N, Khan MU, Kay BA, Khan MR, et al.

J Infect Dis. 1988 Aug;158(2):372-7.

PMID:
3042876
10.
11.

[Examples for vaccines against diarrheal diseases--rotavirus and traveller's diarrhea].

Kollaritsch H, Wiedermann U.

Wien Med Wochenschr. 2007;157(5-6):102-6. Review. German.

PMID:
17427005
12.

Expression of the cholera toxin B subunit (CT-B) in maize seeds and a combined mucosal treatment against cholera and traveler's diarrhea.

Karaman S, Cunnick J, Wang K.

Plant Cell Rep. 2012 Mar;31(3):527-37. doi: 10.1007/s00299-011-1146-3. Epub 2011 Sep 22.

PMID:
21938449
13.

Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination.

Sanchez J, Johansson S, Löwenadler B, Svennerholm AM, Holmgren J.

Res Microbiol. 1990 Sep-Oct;141(7-8):971-9.

PMID:
2101488
14.

From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development.

Svennerholm AM.

Indian J Med Res. 2011 Feb;133:188-96. Review.

17.

Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.

Boyaka PN, Ohmura M, Fujihashi K, Koga T, Yamamoto M, Kweon MN, Takeda Y, Jackson RJ, Kiyono H, Yuki Y, McGhee JR.

J Immunol. 2003 Jan 1;170(1):454-62.

18.

Strategies to overexpress enterotoxigenic Escherichia coli (ETEC) colonization factors for the construction of oral whole-cell inactivated ETEC vaccine candidates.

Tobias J, Svennerholm AM.

Appl Microbiol Biotechnol. 2012 Mar;93(6):2291-300. doi: 10.1007/s00253-012-3930-6. Epub 2012 Feb 16. Review.

PMID:
22350259
19.

Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.

Tamura S, Yamanaka A, Shimohara M, Tomita T, Komase K, Tsuda Y, Suzuki Y, Nagamine T, Kawahara K, Danbara H, et al.

Vaccine. 1994 Apr;12(5):419-26.

PMID:
8023550
20.

Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum.

Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM, Frech SA.

Infect Immun. 2007 May;75(5):2163-70. Epub 2007 Jan 29.

Supplemental Content

Support Center